Delayed esophagectomy for adenocarcinoma is associated with a negative impact on long-term survival and an increased risk of perioperative morbidity

J Surg Oncol. 2024 Mar;129(3):592-600. doi: 10.1002/jso.27513. Epub 2023 Nov 20.

Abstract

Objective: Delayed esophagectomy (DE) following chemoradiation therapy (CXRT) for esophageal carcinoma is undertaken in selected patients. This study aimed to assess both short-term outcomes and long-term survival for patients with adenocarcinoma undergoing DE.

Methods: The National Cancer Database was queried for patients with American Joint Committee on Cancer clinical stage II-III esophageal adenocarcinoma undergoing esophagectomy after CXRT. Patients were categorized as (1) DE, ≥90 days between completion of CXRT and surgery or (2) nondelayed esophagectomy (NDE), <90 days. Cox regression was performed to identify factors associated with mortality.

Results: A total of 8157 patients met criteria. Age >69, nonwhite race, Medicare/Medicaid insured patients preferentially underwent DE. Five-year overall survival (OS) favored NDE (36% vs. 31%, p = 0.008). Cox regression identified DE, clinical stage >T2, or >N0 as factors associated with mortality. Within the DE group, OS favored early cT-status. DE fared worse than NDE in 30- and 90-day mortality (4.5%/11.1% vs. 2.9%/6.5%, p < 0.01/p < 0.001) and margin positive resection (7.1% vs. 4.2%, p < 0.001).

Conclusions: For esophageal adenocarcinoma, DE is associated with decreased OS compared to NDE. For DE, cT-status is prognostic for OS, while cN-status was not. Increased 30-/90-day mortality and margin positive resection rates for DE question whether patients with locally advanced (cT3/T4) primary esophageal adenocarcinoma should undergo intentional DE.

Keywords: adenocarcinoma of the esophagus; esophagectomy; pathologic complete response; prognosis; salvage esophagectomy.

MeSH terms

  • Adenocarcinoma* / surgery
  • Aged
  • Esophageal Neoplasms* / surgery
  • Esophagectomy / adverse effects
  • Humans
  • Medicare
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Retrospective Studies
  • Treatment Outcome
  • United States / epidemiology

Supplementary concepts

  • Adenocarcinoma Of Esophagus